Grandstanding like the FDA's and the NGO's does nothing to keep consumers safe or deal with the real challenges faced by BBU ...
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
BTIG analyst Justin Zelin has reiterated their bullish stance on SNDX stock, giving a Buy rating on November 15.Don't Miss our Black Friday ...
A hefty amount of butter sold at Costco warehouses nationwide has been recalled for containing an “undeclared allergen,” ...
Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...
The Food and Drug Administration released a warning for a recall on organic carrots that may be contaminated by E. coli. The ...
Preclinical studies have shown AT-02 is able to bind to multiple amyloid types and can induce macrophage mediated amyloid phagocytosis and removal. The Food and Drug Administration has granted Orphan ...
As of Nov. 8, Eisai still had lorcaserin listed (PDF) on its virtual pipeline, with Dravet syndrome the sole indication in ...
One person has died and dozens have been sickened, many of them local, across nearly 20 states in an E. coli outbreak the ...
In both TEASE-1 and TEASE-3, gildeuretinol demonstrated a favorable safety and tolerability profile. There were no adverse ...
BTIG raised the firm’s price target on Syndax (SNDX) to $43 from $35 and keeps a Buy rating on the shares. The firm cites the company having ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback